

REMARKS

The Examiner has required a Restriction under 35 U.S.C. 121 and 372 between the following groups

Group 1, claims 1-14, drawn to a solid dosage form.

Group II, claims 15-16, drawn to method for treatment.

Group III, claims 17-18, drawn to a use of a solid oral dosage.


Group IV, claims 19-20, drawn to a process for the manufacture of a solid oral dosage.

Applicants elect without traverse Group 1, claims 1-14 drawn to a solid dosage form.

Please elect the species: hypertension. Claims 13 and 14 are readable thereupon.

Examination on the merits is respectfully requested.

Respectfully submitted,

  
\_\_\_\_\_  
Joseph T. Majka  
Attorney for Applicants  
Reg. No. 30570

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 101  
East Hanover, NJ 07936-1080  
Tel. (862) 778-9499

Date: January 26, 2009